Introduction

Science Corporation has taken a significant step in neurotechnology by implanting its PRIMA vision-restoring chip into the first patient diagnosed with Stargardt disease, marking a major milestone in using retinal prosthetics to address inherited vision loss.

What Happened

The company's chief executive, Max Hodak—former co-founder of Neuralink—announced the successful implantation during TechCrunch Disrupt. The patient, who received the PRIMA device in May, experienced early visual recovery, reportedly seeing a letter after the first rehabilitation session and reading a full word by the second. The implant, a tiny two-millimeter square chip placed at the back of the eye, works alongside camera-equipped glasses that transmit visual data directly to the retina via optical processing.

Why This Matters

Stargardt disease affects approximately 150,000 people worldwide and currently has no cure, gradually destroying central vision by damaging the eye's light-sensing cells. Unlike many existing treatments, the PRIMA system targets the outer retina while potentially preserving the inner retinal pathways that relay signals to the brain. Hodak emphasized that the technology fits broadly within the category of brain-computer interfaces, alongside cochlear implants and other neural prosthetics, expanding the potential for medical BCIs beyond computer control.

Key Takeaways

  • The PRIMA chip is already available in Europe for patients with geographic atrophy, an advanced form of age-related macular degeneration.
  • Science Corporation plans to extend the technology to multiple retinal and neurological conditions, leveraging its experience from the first Stargardt patient trial.
  • Hodak outlined a long-term vision where BCIs become common medical tools, potentially needed by individuals in their 60s and 70s to extend healthy lifespan and cognitive function.
  • The company's broader BCI roadmap includes implantable sensors placed under the skull, resting on the brain's surface rather than penetrating tissue, distinguishing it from some competing approaches.

Conclusion

The successful implantation in a Stargardt patient demonstrates the feasibility of retinal prosthetic technology and opens a pathway for broader neurological applications. As Science Corporation continues its clinical work, the focus will shift to expanding the device's field of view, improving resolution, and validating the approach across an expanding range of medical indications.